Skip to main content
. 2024 May 5;12(5):500. doi: 10.3390/vaccines12050500

Figure A30.

Figure A30

Sensitivity analysis, breakthrough infections with lower respiratory tract infection (LRTD) with 3 or more signs/symptoms associated with respiratory syncytial virus infection in follow-up studies [48,61,85].